NASDAQ:DRTS Alpha Tau Medical Q2 2026 Earnings Report $14.48 -0.41 (-2.75%) Closing price 04:00 PM EasternExtended Trading$14.74 +0.25 (+1.76%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alpha Tau Medical EPS ResultsActual EPS-$0.50Consensus EPS -$0.14Beat/MissMissed by -$0.36One Year Ago EPSN/AAlpha Tau Medical Revenue ResultsActual RevenueN/AExpected Revenue$0.14 millionBeat/MissN/AYoY Revenue GrowthN/AAlpha Tau Medical Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateMonday, August 10, 2026Conference Call Time4:00PM ETUpcoming EarningsAlpha Tau Medical's Q3 2026 earnings is estimated for Thursday, November 19, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 17, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Alpha Tau Medical Earnings HeadlinesAlpha Tau Medical (DRTS) dominates Reddit with 267 comments on Oct. 5October 5 at 10:32 AM | 247wallst.comAlpha Tau to Participate in October Investor ConferencesOctober 5 at 9:45 AM | globenewswire.comA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names distributes income every single Thursday, with payouts reported as high as $1,051 a month. Chief Income Strategist Tim Plaehn breaks down the fund's real Thursday distribution history, how the income is generated, and how to buy it in any brokerage account.October 6 at 1:00 AM | Investors Alley (Ad)Alpha Tau Medical consensus price target raised 23.61% to $18.16September 15, 2026 | msn.comAlpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next.September 15, 2026 | markets.businessinsider.comOramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And MoreSeptember 11, 2026 | seekingalpha.comSee More Alpha Tau Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email. Email Address About Alpha Tau MedicalAlpha Tau Medical (NASDAQ:DRTS) is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue. Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area. The company has evaluated the technology in clinical studies involving several types of solid tumors, including skin, head and neck, oral, breast, pancreatic and other cancers. Alpha DaRT remains an investigational treatment in the jurisdictions where it is being studied, and regulatory status may vary by geography. Founded in 2016, Alpha Tau Medical is headquartered in Tel Aviv, Israel, and has conducted research and clinical development activities in Israel, the United States and other international markets. The company was co-founded by Uzi Soffer, who has served as its chief executive officer, alongside researchers and physicians involved in the development of the Alpha DaRT platform.View Alpha Tau Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
